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Abstract

Introduction and Aims Experiences of buprenorphine‐naloxone (BNX) sublingual film injection are not
well documented or understood. We examined how people who inject BNX film seek and share information
about this practice, document the methods used to prepare BNX film for injection, and report participants'
experiences of this practice. Design and Methods Interviews were (n = 16) conducted with people who
indicated that they had injected BNX film since its introduction onto the Australian market. Semistructured
interviews were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the
data using qualitative description methodology. Results Participants largely reported similar BNX film
preparation techniques, although the texture of BNX film during preparation to inject was reported to be
unusual (gluggy), and there were many varied accounts associated with the amount of water used. Physical
harms reported as associated with injecting BNX film were described (including local and systemic issues);
participants reported injecting the film to enhance its immediate effects, yet generally reported that sublingual
administration provided longer‐lasting effects. Discussion and Conclusions Understanding knowledge
acquisition about injecting new formulations of opioid substitution therapy is crucial in developing more
effective harm‐reduction strategies. Dissemination by peer networks to those who are currently or planning to
inject BNX film regarding the 'gelatine like' texture when mixing, using only cold water and double filtering is
important to ensure safer injecting practices. Findings from this study highlight the importance of peer
networks for the dissemination of harm‐reduction information. Introduction of new formulations
internationally requires more qualitative studies to inform safer practices.
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Introduction and Aims: Experiences of buprenorphine-naloxone (BNX) sublingual film
injection are not well documented or understood. We examined how people who inject BNX
film seek and share information about this practice, document the methods used to prepare BNX
film for injection, and report participants’ experiences of this practice.
Design and Method: Interviews (n=16) conducted with people who indicated that they had
injected BNX film since its introduction onto the Australian market. Semi-structured interviews
were recorded and transcribed. NVivo10 program (QSR International) was used to analyse the
data using Qualitative Description methodology.
Results: Participants largely reported similar BNX film preparation techniques, although the
texture of BNX film during preparation to inject was reported to be unusual (gluggy), and there
were many varied accounts associated with the amount of water used. Physical harms reported as
associated with injecting BNX film were described (including local and systemic issues);
participants reported injecting the film to enhance its immediate effects, yet generally reported
that sublingual administration provided longer-lasting effects.
Discussion: Understanding knowledge acquisition about injecting new formulations of OST is
crucial in developing more effective harm reduction strategies. Dissemination by peer networks
to those who are currently or plan to inject BNX film regarding the ‘gelatine like’ texture when
mixing, using only cold water, and double filtering is important to ensure safer injecting
practices.
Conclusions: Findings from this study highlight the importance of peer networks for the
dissemination of harm reduction information. Introduction of new formulations internationally
requires more qualitative studies to inform safer practices.
Key words: Patient non-adherence, buprenorphine-naloxone, qualitative research, harm
reduction, intravenous drug abuse
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Introduction
Medicines, including those used to treat opioid dependence, have an important, legitimate role in
medical practice, and can make an enormously positive contribution to the health and wellbeing
of many patients (1). However, not all pharmaceuticals are used in accordance with doctors’
directions. The injection of pharmaceutical products developed for oral or sublingual
consumption has been well described in the literature, and this practice has been associated with
a number of individual physical harms (2-6). Notably, the introduction of newer “abusedeterrent” formulations may result in a range of serious and unanticipated harms. Two examples
of this include the introduction of the gel cap formulation of Temazepam©, resulting in a range of
injection related harms such as thrombophlebitis, abscesses and deep venous thrombosis (7), and
the introduction of a less injectable oxycodone formulation in the US, leading to a significant
drop in OxyContin injection, with a concurrent doubling in reported rates of heroin use in some
populations (8).
Opioid substitution therapy (OST) for opioid dependence predominantly involves the use of
methadone or buprenorphine, and has been found to be effective in reducing mortality, HIV
transmission, crime, and other drug use (9-12). In Australia, OST is usually prescribed under the
conditions of supervised dosing. Despite the high level of supervised dosing and, in the case of
buprenorphine, the predominant use of the buprenorphine-naloxone (BNX) products, the
diversion and injection of buprenorphine has been documented in both those receiving OST and
also out of treatment populations (13-15). One Australian study estimated that approximately 9%
of all ‘supervised doses’ of BNX are removed from clients’ mouths at the dosing point (13), a
proportion of which are later injected. Several international studies have also reported the nature,
extent and consequences of injecting BPN (e.g. 3, 16, 17-22).
In late 2011, a new formulation of sublingual BNX registered as Suboxone Film, was introduced
in Australia for the treatment of opioid dependence, with the main clinical rationale being to
reduce aberrant use of BNX. Previous Australian research has highlighted the difficulties of
effectively supervising sublingual BPN or BNX tablets, which usually take between 3 and 10
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minutes for full dissolution of tablets (23). One randomised-controlled trial has found that BNX
film adheres to the sublingual mucosa more rapidly and dissolves faster than BNX tablets,
particularly at high doses (24). US data from 2011-2012 showed that “abuse and diversion” of
BPN and BNX tablets exceeded that of BNX film (25). Given these characteristics, it was hoped
in Australia that BNX film may be (a) quicker to supervise and (b) more difficult to remove from
the mouth than BNX tablets, resulting in less removal of supervised doses from the dosing site
and subsequent diversion or injection of supervised doses in comparison to BNX tablets.
The introduction of the BNX film formulation in Australia has presented a unique opportunity to
examine the transmission of knowledge and behaviours between people who inject
pharmaceutical opioids intended for oral or sublingual consumption. This study was undertaken
as part of a larger mixed-methods post-marketing surveillance study to monitor the extent of
diversion and injection of BNX film in Australia (26). To date, no qualitative studies have
examined the context, extent and nature of BNX film injection. Given the potential for severe
harms associated with the injection of pharmaceutical opioids intended for oral/sublingual
consumption, understanding how information about injecting new formulations is learned and
shared is crucial in understanding how best to disseminate harm reduction information and target
interventions. Specifically, this study’s aims were:
a. To examine how people who inject BNX film seek and share information about this
practice, and
b. To document the methods used to prepare BNX film for injection and participants’
experiences.

Method
This qualitative study was undertaken as part of a larger mixed-methods post-marketing
surveillance study of the diversion and injection of BNX film (27).

Qualitative research

interviews with 16 people who reported injecting BNX film were conducted by trained
interviewers during September 2012 to March 2013, approximately 12 months after the
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introduction of the Film in Australia. Participants were recruited from among people currently in
OST and recruited into the wider post-marketing surveillance studies of BNX film across three
sites (Adelaide, Sydney, and Melbourne). Participants reflected the range of treatment settings
and included a mix of public, private and general practice prescribers.

Participants who

indicated they had injected BNX film in the post-marketing surveillance interview and who
indicated that they were willing to participate in another interview regarding BNX injecting were
approached.

All those approached consented to participate in the study which included a

recorded face to face interview.

Measures
Participants were surveyed using a semi-structured interview schedule, with the interview
recorded and then transcribed. Questions included commencement of injection of various OST
medications, and more specifically questions focussed on BNX Film including: recent frequency
of use, acquisition practices, preparation for injection, reasons for and experiences with injecting,
sublingual use compared to injection, knowledge procurement, and concerns. These questions
were designed to elicit narratives around injection of BNX film more generally.

Procedure
Eligible participants were invited to participate in an interview specifically relating to injection
practices with BNX film. Interviews were conducted at cafes or in an office location
(independent of OST services) and all participants provided informed consent to be interviewed
and recorded. Participants were reimbursed either a $40 voucher (NSW, SA) or $40 cash (VIC)
for their time and travel expenses, with interviews taking approximately 40 minutes.

Ethical approval
Approval for the qualitative interviews of people who inject BNX film was provided by the
Sydney Local Health District Human Research Ethics Committee (HREC), University of New
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South Wales HREC, Alfred Hospital HREC and the University of Adelaide HREC. The study
conforms to the provisions of the Declaration of Helsinki (as revised in Tokyo 2004).

Data Analysis
Data analysis was conducted using the NVivo10 program (QSR International.). To ensure
consistency, a selection of early transcripts was reviewed independently by three researchers.
The analysis involved the use of qualitative description (28) where participants’ responses were
coded by question responses, and subcategories of coded data were derived by grouping the
experiences of the participants. Qualitative description does not involve interpretation of the data
using themes rather it describes what the participant has stated during interviews, and allows for
understanding of a topic from the participants’ viewpoint and “entails a kind of interpretation
that is low inference, or likely to result in easier consensus among researchers” (29). Content
analysis of this nature allows an intense examination of language conducive to “classifying large
amounts of text into an efficient number of categories that represent similar meanings” (30).
This methodology is well-suited to research which seeks to examine health behaviours (31).
Similarities and differences in participants’ responses to the various questions posed were
examined. Descriptive statistics are also provided for demographic characteristics and details of
current opioid treatment.

Participants
Sixteen participants were interviewed. Most participants were male (n=13, 81%), with an
average age of forty years (range 20-56 years). Participants were mainly unemployed (11 of 16,
or 69%), spending an average of 10 years in education (range 7-12 years) and living in rental
accommodation. The majority (n=13, 81%) were receiving opioid substitution treatment (OST)
at the time of interview (twelve receiving BNX film and one receiving methadone). Participants
prescribed BNX reported an average 16mg buprenorphine daily (range 8-32mg) at the time of
interview.
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Results
Frequency of injection
Six participants reported injecting BNX film daily (five reported >5 times a day), two reported
weekly use, three participants reported occasional use (once per month or less), and five had
injected at least once.

Knowledge Acquisition
Participants reported a variety of sources for learning how to inject the film with most (56%,
n=9) through the injecting networks of friends and acquaintances, either through being told how
to do so (P3, n=6), or by observing others’ practices (P11, n=3).
I learnt from my mate how to do it, ah, not a mate as much an acquaintance and
they, pretty much just said, what I do is basically the same drill as you would mix
up you know anything (P3).
I learnt through watching my friends, again, just they were using a lot more than
I was. (P11).
Five of the participants reported following the advice given, and as can be seen in the extract
above one was told to continue with their usual practice (P3). One participant reported first
watching friends and then one of those friends “recommending that I not try a lot at once so they
only cut a quarter off the film and gave it to me (p11).” This person had just taken prescribed
Methadone and reported going into precipitated withdrawal immediately after injecting BNX
film.
Other participants (44%, n=7) cited experimentation (P13; n=3) and personal experience (P14;
n=4) as their primary source of knowledge, for example:
I just tried it again, yeah, and put a lot of water with it because I tried to put a
little bit of water with it but it went to like a jelly sort of thing so I put a bit extra
water with it and Bob’s your uncle (P13).
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Just personally through injecting pills and heroin and that, just sort of translated
to that (P14).
The Internet was also identified as a source of ‘extra’ information regarding injection of BNX
film by two participants:
I was mainly checking (the Internet) to find out whether you could inject it you
could say whether it was injectable or whether people had withdrawals, bad
withdrawals from it ... The posts on the net could tell you whether you’re able to
do it (P4).
Both participants who investigated intravenous use of BNX film via the Internet also asked
friends (n=1), and used their own personal experience (n=1). One participant mentioned hearing
through the ‘grapevine’, with another commenting that a number of people had approached him
asking how to inject it.

Preparation of the BNX film for injection
Participants provided mixed accounts of the ease with which the film may be dissolved. The
general impression given by participants is that BNX film dissolves quite readily in water,
usually with a spoon or the syringe plunger to mix it up (75%, n=12), with comments such as
“dissolves quite readily, mix it with the plunger” (P16), and “Put into syringe add hot water and
keep shaking until dissolved” (P5) describing the process. There was consistency across the 8
participants who reported that BNX film becomes ‘gluggy’, or gelatine-like when wet, either in
the mouth via the saliva or when water is added to inject. This included 4 participants who also
reported it dissolved readily in water, with comments made such as “[The BNX film] is like
chewing gum” (P14), “[the BNX film] goes all yucky when wet/ turns into gel” (P13) and “bit
more viscous than water/ orangey white solution” (P16).
The majority of participants reported only injecting a ‘dry’ BNX film dose (never been in
someone’s mouth, 94%, n=15) rather than a ‘wet’ dose (removed from the mouth). A number of
participants (60%, 9 of 15) reported either slightly heating the water or adding boiling water; six
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(40%) used unheated water. One participant reported using lukewarm water when mixing ‘wet’
BNX film and unheated water when mixing with ‘dry’ BNX film. The temperature of the water
did not appear to affect the gelatine-like nature of the film with: four (50%) of those participants
reporting this phenomenon not heating the water; and, two (25%) of those who reported it mixed
readily not heating the water.
Reports regarding the volume of water required varied considerably across the sample. Several
participants (5 of 8) noted that with low volumes of water the substance became ‘gelatine like’
requiring the addition of more water to dilute the mixture (e.g. around 80 to 100 units in total of
water for 2-4mg film). However, participants also reported the BNX film dissolved readily using
less water (e.g. 40-50 units in total for 2-4mg of film).
Twelve (75%) participants reported using a filter: either a cigarette filter (44%, n=7) or cotton
wool (25%, n=4) and one did not mention the kind of filter used. It should be noted that all of
those reporting gelatine like characteristics had used a filter of some form, whereas only 4 (50%)
of those not reporting such characteristics using filters. The excerpt below was a typical
description on the process of BNX Film preparation prior to injection:
I just put it in water, just like you would heroin or Suboxone or anything like
that…used a filter to mix it around ‘til it was a different colour, and mixed it
around and then just sucked it up, filtered it with a cigarette filter and just shot it
up…I didn’t heat it at all. Just mix up by itself, it kind of goes like a chewing gum
as you mix it (P14).

Experiences with BNX film injecting
Participants were asked if they had noticed any differences between the experiences of using
BNX film sublingually compared to injecting it. Around half of the participants who commented
(57% or 8 of 14), reported that injecting BNX film provided a more rapid or immediate effect
than sublingual use:
You feel it faster [injecting BNX film], you’re not as sick as quickly, it makes you
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feel better quickly …it just makes you feel better a whole lot quicker because
otherwise [taking it sublingually] you’ve got to wait an hour to two hours for it to
kind of really make you feel better (P15).
Half of those who reported rapid effects used BNX film daily, with others reporting occasional
use (n=2), weekly use (n=1) and single use (n=1).
In the excerpt below, the participant stated that the medication works better when used
sublingually or as directed (43%; or 6 of 14):
I think it might makes you hang out quicker [When injected]…Under my mouth it
lasts longer and it’s better…like I said after that though it wears out
easier…‘cause I’d wake up in the morning better fresher and I go get my dose
easier if I had it under my tongue (P8).
Five participants, of whom three had used daily, did describe feeling slightly different in their
mood state or in their bodily experience after injection of BNX film. For example participants
described getting a “little perk, like more energy” (P4), or a “tingling sensation and motivate you
in that sense” (P5). Other participants (n=2) reported no physical difference between sublingual
or intravenous administration of BNX film.

Adverse effects arising from injecting BNX film
Eleven participants (69%) reported some concerns (and some (n=4) reported more than one
concern regarding physical health and veins issues) arising from injecting BNX film. Issues
included problems with local injecting sites (55%, n=6); broader health concerns such as
perceived heart disturbance and puffy hands (37%, n=4); precipitated withdrawal from injecting
BNX film after using other opiates (e.g. Within a short time my world was coming to end for all I
knew I thought it was and I was terrified (P11)(20%, n=3)); and, having a ‘dirty hit’ which was
assumed to be the result of injecting a dose that had come from someone’s mouth (13%, n=2).
Those who reported local vein problems provided descriptions such as:
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Destroys your veins, absolutely destroys your veins. Use a vein once and that’s it,
it has gone for two weeks, and then it’s narrowed and it’s clogging and if you use
it too often it’s gone completely. I have got no usable veins in my arms or hands
at all. (P1).
P1 had previously stated that injection of Subutex tablets had destroyed his veins. Of the six
participants who reported local injecting site issues, five reported that they had also had previous
veins issues when injecting Subutex.
Two participants who mentioned having vein problems also reported having chest pain after
injecting BNX film with both providing similar narratives, for example:
I was worried for about one week because the section near my heart where I can
actually feel, it feels like it’s put a resin, a line, a gunky line going into the heart.
I could actually feel that for the last 3 or 4 days …I’m assuming that it has worn
off it’s coming off my body which is very happy, because I was worried about
having a heart attack or something (P4).
Both participants reported frequent injection of BNX film (2-5 times a day). Neither of
these participants sought help for their chest pain symptoms, nor did those who had been
affected by precipitated withdrawal.

Discussion
This qualitative study examined the experiences of people who had injected BNX film across
three Australian jurisdictions at a time when BNX film was being introduced. Our study found
that, consistent with previous studies examining knowledge transfer (32, 33), friends and other
people who inject drugs remained the most common source of knowledge regarding injecting
new pharmaceutical preparations, either by verbal instruction or direct observation (34).
Experimentation (35) and prior personal experience of injecting other substances were also
drawn upon to inform injecting practices with the BNX film. Such self-experimentation may at
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times be associated with the potential for harm – for example, nearly two-thirds of participants
reported heating their film-water solution prior to injecting – yet recent laboratory findings
suggest heating pharmaceutical opioids may result in greater particulate matter, and increase the
risk of thrombosis or infection (36). The internet still does not appear to be a common source of
such specific injecting information in this group of individuals.
We also found that participants across sites reported similar preparation techniques, with
dissolution in water (either heated or unheated) and filtering using cigarette or cotton filters. Our
finding that wheel filters were not commonly used represents one opportunity to target harm
reduction messages to those who inject BNX film, as a double filtering process including a
wheel filter has previously been shown to be optimal for other pharmaceutical opiates (30). Half
of the participants noted that when mixing the BNX film preparation it became ‘gelatine like.’
This finding is not surprising considering the BNX film consists of hydroxypropyl
methylcellulose, a thickener which is soluble but viscous in cold water, and virtually insoluble in
a mixture of hot water and alcohol (37). There were however many and varied accounts of the
effects of different volumes of water on the solution such that it is difficult to establish a reliable
pattern. The findings from this study, taken in context of the existing evidence suggesting that a
greater volume of water may reduce morphine crystallisation, indicates that harm reduction
messages should include specific information about volume of water and temperature of water
when preparing BNX film for injection (30).
Most participants reported injecting the film to enhance its immediate effects, either for more
rapid onset, or greater intoxication, but participants generally reported that sublingual
administration

provided

longer-lasting

effects.

These

are

consistent

with

expected

pharmacokinetic effects of different routes of administration (38). Over two thirds of participants
reported experiencing problems with injecting BNX film including vein issues, precipitated
withdrawal, heart concerns and dirty hits. None of those reporting cardiac symptoms or
precipitated withdrawal sought medical assistance, and importantly, participants reported a
reticence to seek medical assistance when experiencing what they described as serious physical
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symptoms. This provides further evidence for concerns raised about the barriers to seeking help
for people who inject drugs, especially those who inject their own take-away prescribed OST
(34-36).
These findings reinforce the important role of peer-based education strategies in reducing
potential harms associated with injecting the BNX film and a need to disseminate this
information to users (33, 39, 40). Although the safest route of administration is sublingual,
information needs to be tailored to those who inject BNX film. Such advice could include using
only cold water and double filtering to minimise the injection of the ‘gelatine-like’ texture,
microbes and other particulate matter. Low threshold services such as needle and syringe
programs and peer based services provide opportunities to deliver harm reduction advice to this
target group (39, 40). In some countries, injectable opioid treatment options are available for
those clients unable or unwilling to cease injection (37, 38).
A limitation of this study was the small sample size and exploratory in nature of the study, and
the heterogeneity of prescribing practice across the jurisdictions; that is, each jurisdiction was in
a different phase of rolling out BNX film as an OST alternative to buprenorphine-naloxone
tablets. One jurisdiction, advanced in this process, therefore yielded the majority of data. Within
the sample there was considerable agreement among the narratives across the recruitment sites,
indicating that the sample size in this study, while small, was appropriate for this exploratory
nature of this work

Conclusion
Understanding how knowledge is acquired about injecting new pharmaceutical formulations that
are intended to reduce injection is crucial in developing more effective harm reduction strategies.
The data illustrate different practices in preparing the film that do not reflect the best evidence,
with respect to heating of water and use of wheel filters. Participants reported peer-networks as
a source of knowledge around these preparation practices, highlighting the opportunities for
using these existing networks to help transfer knowledge about reducing harm with new
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formulations. Recommendations arising from the data gathered in this study include: further
qualitative work on knowledge acquisition of injecting practices when new preparations of
pharmaceutical opioids are introduced; and the specific ways in which peer-networks can be
harnessed for the dissemination of harm reduction messages when novel preparations such as the
film are introduced. Although we are well aware of the harms resulting from intravenous use of
tablets this study has described such use with a new formulation with an unusual texture that
may result in a variety of harms not seen with injection of tablets and as such it is important to
continue to monitor this behaviour.
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